|
|
Acadia Pharmaceuticals, Inc. - Comparative Business Analysis Snapshot
Business Description
Acadia Pharmaceuticals, Inc.. The Group's principal activity is to discover, develop and commercialize small molecule drugs for the treatment of central nervous system disorders.It has a product candidate in Phase II for chronic pain and a product candidate in Phase I for glaucoma both in collaboration with Allergan Inc and ACP-106 in IND-track development. The Group currently developing a portfolio consisting of four most advanced product candidates including pimavanserin, which is in Phase III development for the treatment of Parkinson's disease psychosis and retained worldwide commercialization rights to pimavanserin. It operates in the United States and Europe.
Competitor Analysis
This analysis compares Acadia Pharmaceuticals, Inc. with three other companies in closely related industry sectors.
The full Comparative Business Report is available to Subscribers or may be purchased individually. The full report generally includes the following sections:
- Sales Analysis: Recent Sales, Sales Growth, Sales per Employee
- Recent Stock Performance
- Company Valuation Ratios: Price/Earnings, Price/Book Value
- Price/Sales and 52 Week Price change
- Dividend Analysis
- Profitability Analysis: Gross Profit Margin, EBITDA Margin
- Earnings Before Extraordinary Items
- Inventory Analysis
- Research and Development Expenses
- Financial Position: Long Term Debt/Equity, Days Accounts Receivable, Days Inventory
- R&D Expenses/Sales
Not the Report you are looking for? Click here for more browsing options.
|
|
|
|
|
